Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Amgen

(

AMGN

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.8%. By the end of trading, Amgen rose 88 cents (1.1%) to $82.91 on light volume. Throughout the day, 3.2 million shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock ranged in a price between $81.98-$83.07 after having opened the day at $82.07 as compared to the previous trading day's close of $82.03. Other companies within the Drugs industry that increased today were:

Skystar Bio-Pharmaceutical Company

(

SKBI

), up 19.7%,

Savient Pharmaceuticals

(

SVNT

), up 16.8%,

Prima Biomed Ltd. ADR

(

PBMD

), up 11.5%, and

Insmed

(

INSM

), up 10.1%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $63.43 billion and is part of the

health care

sector. The company has a P/E ratio of 17.6, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 27.8% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front,

Peregrine Pharmaceuticals

(

PPHM

), down 78.5%,

Questcor Pharmaceuticals

(

QCOR

), down 36.7%,

MEI Pharma

(

MEIP

), down 17.6%, and

Aoxing Pharmaceutical Company

(

AXN

), down 11.1%, were all laggards within the drugs industry with

Alexion Pharmaceuticals

(

ALXN

) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null